CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Pfizer Inc. v. Mylan Inc.

1:09-cv-00441

Overview

Case Number 1:09-cv-00441
Filing Date 2009-06-15
Status Terminated
Termination Date 2011-06-30
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Matrix Laboratories Inc. Operating Company

Represented By

3 Attorneys Listed

Warner-Lambert Company NPE (Individual / Inventor)

Represented By

1 Attorneys Listed

Pfizer Inc. Operating Company

Represented By

1 Attorneys Listed

Plaintiff

Warner-Lambert Company LLC Operating Company

Represented By

1 Attorneys Listed

Pfizer Ireland Pharmaceuticals Operating Company

Represented By

1 Attorneys Listed

Counter Claimant

Mylan Inc. Operating Company

Represented By

3 Attorneys Listed

Counter Defendant

Matrix Laboratories Limited NPE (University / Research)

Represented By

3 Attorneys Listed

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 4 proceedings
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (4 found):
U.S. Courts: 4
U.S. District Court 2009-12-08
1:09-cv-00943

Pfizer Inc. v. Dr. Reddy's Laboratories Ltd.

Asserted Patent
Status: DED
U.S. District Court 2009-12-03
1:09-cv-00924

Pfizer Inc. v. Kremers Urban LLC

Asserted Patent
Status: DED
U.S. District Court 2008-12-17
1:08-cv-07231

Pfizer Inc. v. Apotex Inc.

Asserted Patent
Status: ILND
U.S. District Court 2008-03-24
1:08-cv-00164

Pfizer Inc v. Ranbaxy Laboratories Limited

U.S. Family Sibling (["US6087511", "US2674740", "US6274740"])
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

3 Patents

There are 3 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5969156
Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
Filed: 1996-07-08
Issued: 1999-10-19
Expired (Term Ended)
Expires: 2016-07-08
US6087511
Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
Filed: 1996-07-16
Issued: 2000-07-11
Expired (Term Ended)
Expires: 2016-07-16
US6274740
Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethy)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
Filed: 2000-09-07
Issued: 2001-08-14
Expired (Term Ended)
Expires: 2020-09-07

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

15

Dispositive

0

Granted

0

Denied

0

Pending / Review

15

Motions by Category

Motion to Stay 8 Procedural / Extension Motion 7

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
Joint STIPULATION TO EXTEND TIME to EXTEND discovery conclusion to March 12, 2010 - filed by Matrix Laboratories Inc., Matrix Laboratories Limited, Mylan Inc.. ...
Entry #49 • 2010-01-11 Document →
Procedural / Extension Motion Pending / Under Review
REPLY BRIEF re 37 MOTION for Leave to File An Amended Answer, Separate Defenses and Counterclaims of Defendants filed by Matrix Laboratories Inc., Matrix Labora...
Entry #46 • 2009-12-21 Document →
Procedural / Extension Motion Pending / Under Review
ANSWERING BRIEF in Opposition re 37 MOTION for Leave to File An Amended Answer, Separate Defenses and Counterclaims of Defendants, filed by Pfizer Inc., Pfizer ...
Entry #43 • 2009-12-11 Document →
Procedural / Extension Motion Pending / Under Review
DECLARATION of Daniel C. Mulveny, Esquire re 43 Answering Brief in Opposition to Motion for Leave to File an Amended Answer, Separate Defenses and Counterclaims...
Entry #44 • 2009-12-11 Document →
Procedural / Extension Motion Pending / Under Review
MOTION for Leave to File An Amended Answer, Separate Defenses and Counterclaims of Defendants - filed by Matrix Laboratories Inc., Matrix Laboratories Limited, ...
Entry #37 • 2009-11-20 Document →
Procedural / Extension Motion Pending / Under Review
NOTICE OF MOTION by Matrix Laboratories Inc., Matrix Laboratories Limited, Mylan Inc. re 37 MOTION for Leave to File An Amended Answer, Separate Defenses and Co...
Entry #38 • 2009-11-20 Document →

Docket Entries

(65 total)
Pleading / Complaint

COMPLAINT filed against Matrix Laboratories Limited, Matrix Laboratories Inc., Mylan Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 03110000000000597906.) - filed by Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, Warner-Lambert Company LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(dzs, ) (Entered: 06/15/2009)

Entry #1 • 2009-06-15
1
Pleading / Complaint

COMPLAINT filed against Matrix Laboratories Limited, Matrix Laboratories Inc., Mylan Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 03110000000000597906.) - filed by Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, Warner-Lambert Company LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(dzs, ) (Entered: 06/15/2009)

Entry #1 • 2009-06-15
2
Pleading / Complaint

COMPLAINT filed against Matrix Laboratories Limited, Matrix Laboratories Inc., Mylan Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 03110000000000597906.) - filed by Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, Warner-Lambert Company LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(dzs, ) (Entered: 06/15/2009)

Entry #1 • 2009-06-15
2
Pleading / Complaint

COMPLAINT filed against Matrix Laboratories Limited, Matrix Laboratories Inc., Mylan Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 03110000000000597906.) - filed by Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, Warner-Lambert Company LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(dzs, ) (Entered: 06/15/2009)

Entry #1 • 2009-06-15
2
Pleading / Complaint

COMPLAINT filed against Matrix Laboratories Limited, Matrix Laboratories Inc., Mylan Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 03110000000000597906.) - filed by Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, Warner-Lambert Company LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(dzs, ) (Entered: 06/15/2009)

Entry #1 • 2009-06-15
2

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc